Emerging Options in Osteoporosis
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
HF Management for Patients with Comorbid Conditions
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
AI and Hair Loss: Measuring Progress with Data-Driven Insights
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?